Phase I, Multicentre, Open Label, Single Dose, Dose-ranging Clinical Trial to Investigate the Safety and Tolerability of a Gene Therapy rAAV2/5-PBGD for the Treatment of Acute Intermittent Porphyria

Trial Profile

Phase I, Multicentre, Open Label, Single Dose, Dose-ranging Clinical Trial to Investigate the Safety and Tolerability of a Gene Therapy rAAV2/5-PBGD for the Treatment of Acute Intermittent Porphyria

Completed
Phase of Trial: Phase I

Latest Information Update: 31 May 2016

At a glance

  • Drugs AMT 021 (Primary)
  • Indications Acute intermittent porphyria
  • Focus Adverse reactions
  • Sponsors Digna Biotech
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 31 May 2016 According to an uniQure media release, results from this trial were published in the Journal of Hepatology.
    • 06 Apr 2015 Top-line, 1-year follow-up data has been reported, according to a uniQure media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top